Celldex Therapeutics CLDX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's financing cash flow?
- Celldex Therapeutics (CLDX) reported financing cash flow of $327K in Q1 2026.
- How has Celldex Therapeutics's financing cash flow changed year-over-year?
- Celldex Therapeutics's financing cash flow increased by 61.9% year-over-year, from $202K to $327K.
- What is the long-term trend for Celldex Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Celldex Therapeutics's financing cash flow has grown at a -69.4% compound annual growth rate (CAGR), from $272.4M to $2.39M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.